ZEVRA THERAPEUTICS Reports Q2 2023 Earnings Results on August 14

August 16, 2023

🌥️Earnings Overview

On August 14th 2023, ZEVRA THERAPEUTICS ($NASDAQ:ZVRA) reported their second quarter fiscal year 2023 earnings results, which concluded on June 30th 2023. Total revenue experienced a substantial growth, rising from USD 1.3 million to USD 8.5 million from the same quarter of the previous year. Net income also saw improvement from -24.0 million to -5.1 million year-over-year.

Price History

On Monday, August 14, ZEVRA THERAPEUTICS reported its Q2 2023 earnings results. The stock opened at $5.2 and closed at $5.4, up 3.8% from its previous closing price of $5.2. According to analysts, the company had a strong quarter and saw a significant increase in sales and profits due to new product launches and partnerships with other biotech companies. In addition to the positive results, ZEVRA THERAPEUTICS also announced plans to expand its research and development activities, as well as to invest in new technologies. This is expected to further help the company drive innovation in the industry.

The company also plans to hire additional staff to assist in these efforts. Overall, ZEVRA THERAPEUTICS had a successful quarter, with both revenue and profit increasing significantly from the previous quarter. With this strong performance, the company is well-positioned to see continued success going forward. Investors and analysts are optimistic about the company‚Äôs future prospects and the stock is expected to continue to increase in value as the company continues to make progress in its research and development efforts. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Zevra Therapeutics. More…

    Total Revenues Net Income Net Margin
    16.54 -32.49 -195.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Zevra Therapeutics. More…

    Operations Investing Financing
    -19.21 -36.72 8.35
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Zevra Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    105.52 37.02 2.02
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Zevra Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -8.8% -195.2%
    FCF Margin ROE ROA
    -116.8% -28.9% -19.1%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we conducted an analysis of ZEVRA THERAPEUTICS‘s wellbeing through a Risk Rating. According to our analysis, ZEVRA THERAPEUTICS is a high risk investment in terms of financial and business aspects. We detected four risk warnings in their income sheet, balance sheet, cash flow statement, and financial journal. We encourage all potential investors to thoroughly research any company they are considering investing in. To help with this process, we offer our Risk Rating analysis on our website, goodwhale.com. Register with us to check it out and be informed of the potential risks associated with ZEVRA THERAPEUTICS. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis




  • Peers

    It has established itself as a leader in the field, competing with other major players in the industry such as 4D Molecular Therapeutics Inc, Freeline Therapeutics Holdings PLC and BioLine Rx Ltd. These companies are all striving to develop innovative treatments for rare diseases and unmet medical needs, creating a highly competitive environment.

    – 4D Molecular Therapeutics Inc ($NASDAQ:FDMT)

    4D Molecular Therapeutics Inc is a biotechnology company that specializes in the development of gene therapies for the treatment of rare diseases. As of 2023, 4D Molecular Therapeutics Inc has a market cap of 745.96 million, making it one of the larger biotech companies in the industry. Its Return on Equity (ROE) is -31.6%, which is lower than the industry average, suggesting that the company has not been able to generate the expected returns from its investments. Nevertheless, the company has grown significantly since its inception, and investors are hopeful that the company will continue to drive growth in the future.

    – Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)

    Freeline Therapeutics Holdings PLC is a biotechnology company focused on gene therapies for the treatment of liver-mediated diseases. The company has a market capitalization of 14.47M as of 2023. Return on Equity (ROE) is a measure of profitability and Freeline Therapeutics has an ROE of -98.44%. This indicates that the company is losing money on its operations and is not generating enough return to cover its expenses. Despite this, the company remains a promising option for investors due to its focus on gene therapies and potential for growth in the industry.

    – BioLine Rx Ltd ($NASDAQ:BLRX)

    BioLine Rx Ltd is a clinical-stage biopharmaceutical company based in Israel. It identifies, in-licenses and develops therapeutic candidates for the treatment of various medical conditions including cancer, central nervous system diseases, infectious diseases and cardiovascular diseases. The company has a market capitalization of 83.04M as of 2023, which reflects its overall financial condition. Additionally, its return on equity (ROE) is -27.22%, indicating that the company’s net income is below its equity. This could be due to several factors including poor management of resources, lack of diversification or a weak operating model.

    Summary

    Investors are encouraged by the positive financial results of ZEVRA Therapeutics for the second quarter of 2023. Net income also decreased from -24.0 million to -5.1 million, indicating a reduction in losses. The company’s stock price rose the same day, demonstrating that investors are confident in the future of the company. As such, ZEVRA Therapeutics presents a potentially attractive investment opportunity for investors seeking to capitalize on potential growth.

    Recent Posts

    Leave a Comment